Efficacy of light therapy for perinatal depression: a review by Shannon K Crowley & Shawn D Youngstedt
Crowley and Youngstedt Journal of Physiological Anthropology 2012, 31:15
http://www.jphysiolanthropol.com/content/31/1/15REVIEW Open AccessEfficacy of light therapy for perinatal
depression: a review
Shannon K Crowley1,2* and Shawn D Youngstedt1,2,3Abstract
Perinatal depression is an important public health problem affecting 10% to 20% of childbearing women. Perinatal
depression is associated with significant morbidity, and has enormous consequences for the wellbeing of the
mother and child. During the perinatal period, treatment of depression, which could affect the mother and child
during pregnancy and lactation, poses a complex problem for both mother and clinician. Bright light therapy may
be an attractive treatment for perinatal depression because it is low cost, home-based, and has a much lower side
effect profile than pharmacotherapy. The antidepressant effects of bright light are well established, and there are
several rationales for expecting that bright light might also be efficacious for perinatal depression. This review
describes these rationales, summarizes the available evidence on the efficacy of bright light therapy for perinatal
depression, and discusses future directions for investigation of bright light therapy as a treatment for perinatal
depression.
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Perinatal depression refers to depressive syndromes
with onset during pregnancy or within 12 months
after delivery [1]. Research findings suggest that be-
tween 10% and 20% of pregnant women experience a
new episode of depression during pregnancy (ante-
partum depression) [2-4].
The prevalence of postpartum depression (PPD) is also
estimated to be between 10% and 20% [3,5-7], with
higher rates among women who had suffered from ante-
partum depression. Rates of perinatal depression seem
to be particularly high in women with a prior history of
depression, with estimates ranging from 25% to 50% [8].
Additional psychosocial factors which may increase a
woman’s risk for development of perinatal depression in-
clude single marital status, chronic illness, alcohol use
during pregnancy, and lower socioeconomic status [9].
As during other times, risk of depression during the
perinatal period may be influenced by genetic vulnerabi-
lity. Additionally, the perinatal period may be a time of
substantial vulnerability to affective illness due to the* Correspondence: cornelsk@mailbox.sc.edu
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and reproduction in any medium, provided therapid fluctuation in hormone levels during pregnancy,
and more dramatically, during the postpartum period
[9,10]. During pregnancy, depression and co-morbidities
such as stress and anxiety appear to have a direct ad-
verse biological impact on the intrauterine environment,
and are linked to obstetric complications such as pre-
term labor, pre-eclampsia, and anemia, as well as adverse
neonatal outcomes such as low birth weight, neonatal
distress, and other neonatal abnormalities [11-13]. Long-
term child health outcomes affected by antepartum de-
pression include increased risk for neurodevelopmental
disorders, motor difficulties, emotional and behavioral
problems, and adolescent depression [11,12,14].
Postnatally, maternal parenting behavior may be ad-
versely affected by PPD, and this can have detrimental
consequences on child behavioral development. Children
of mothers who had suffered PPD are at increased risk
for development of depression, anxiety disorders (inclu-
ding panic disorder), emotional maladjustment patterns,
violent behavior, and other conduct disorders such as at-
tention deficit hyperactivity disorder [15-18].
Treatment of depression during pregnancy and post-
partum poses a complex problem for both mother and
clinician. Many mothers feel guilty or fearful of their
feelings during a time in which they assume they shouldMed Central Ltd. This is an Open Access article distributed under the terms of the
reativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution,
original work is properly cited.
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toms and opting to ‘suffer in silence’. Antidepressant use
during pregnancy has been linked to multiple harmful
effects to the infant, including persistent pulmonary
hypertension, cardiac abnormalities, and neonatal with-
drawal and toxicity [19-21].
Antidepressant use in mothers could also potentially
harm the breastfeeding infants. A recent meta-analysis of
67 studies of antidepressant levels in breastfeeding infants
found that out of 15 different antidepressants, all were de-
tectable in breast milk at varying levels [22]. However, the
available evidence on the effects of antidepressants during
lactation on drug levels in the nursing infant is limited,
and largely derived from short duration studies with small
sample sizes. Studies have shown that antidepressant
drugs or their metabolites are not always found in the
child’s serum, even though they may be detectable in
breast milk [22,23]. For example, studies have found that
levels of sertraline in infant serum were low to negligible
in breastfeeding mother-infant pairs, in which the mothers
were taking clinically relevant doses of sertraline [24,25],
one of the most commonly prescribed antidepressants for
breastfeeding mothers. However, it is unknown whether
nursing infants might be sensitive to these low levels, par-
ticularly with chronic exposure. To date, there has been
virtually no investigation of long-term child health out-
comes from exposure to maternal antidepressant medica-
tion during breastfeeding. This is especially true for the
modern selective serotonin reuptake inhibitors (SSRIs), as
there are no studies with adequate follow-up of long-term
child health outcomes [23,26]. It is noteworthy that no
medication has been FDA-approved for PPD [11].
Notwithstanding the evidence of risks of antidepres-
sant treatment for perinatal depression, many mental
health providers have concluded that the detrimental
effects of untreated maternal depression might pose an
even greater threat to maternal and child health out-
comes. There is some thought that adverse effects of
antidepressant treatment on the nursing infant can be
minimized by scaling back the dose [4], though this
strategy might also reduce the efficacy of the drug for
the mother.
Nonetheless, legitimate concerns about possible ad-
verse effects of antidepressant medications on the
developing fetus or newborn have led many women
to refuse pharmacotherapy during pregnancy or while
breastfeeding. For mothers who choose to take anti-
depressants during the postpartum period, many forgo
the myriad benefits of breastfeeding in order to take
antidepressants.
Psychotherapy is apparently an effective treatment for
perinatal depression [27,28]. However, due to logistical
issues, such as childcare arrangements and expenses,
women with perinatal depression might also be lesssuitable for psychotherapy than other depressed indivi-
duals. Estimates indicate that only about 15% of women
with PPD are receiving treatment [29]. Thus, alternative
or adjuvant treatments for perinatal depression are
needed.
Rationale for bright light therapy of perinatal
depression
Bright light therapy may be an attractive treatment for
perinatal depression because it is low cost, home-based,
and has a much lower side effect profile than pharmaco-
therapy [30]. Moreover, the efficacy of bright light for
other types of depression has been well established.
Particularly well-documented is the efficacy of bright
light therapy for winter depression, for which bright
light is generally regarded as the first line of treatment
[31]. The utility of light for winter depression also has
considerable intuitive appeal, as seasonal variation in
mood are experienced my much of the population, and
clearly attributed to fluctuations in light [32].
Less well recognized is that, in industrial societies, ave-
rage levels of exposure to bright light (> 1,000 lux) ave-
rage only about 1 h per day even in good weather
conditions [33], and these levels might be inadequate
for mood regulation in susceptible individuals. More-
over, accumulating evidence indicates that bright light
might be equally efficacious for non-seasonal depression
[30,34,35], as well as other morbidities, including dis-
turbed sleep [36,37], fatigue [38,39], and neuroendo-
crine abnormalities [40].
There are several factors related to the pathophysi-
ology of depression and response to light which might
make bright light especially suitable for perinatal depres-
sion. First, women with perinatal depression might re-
ceive very low light exposure. Pregnancy, particularly in
late gestation, may make mobility difficult for some
women, thus reducing time spent outdoors. After deli-
very, women may also experience lower levels of illu-
mination, with increased time spent indoors caring for
their infant who may often sleep during the day. Con-
sistent with this notion are findings of seasonality of
PPD, with increased risk of PPD associated with delivery
during fall and early winter months [41,42] when day-
light is of significantly shorter duration. Although a
study by Wang et al. did not confirm differences in
light exposure of postpartum women vs. matched
control women who were not within 1 year postpar-
tum [43], this remains a tenable hypothesis.
Second, there is some evidence that circadian malsyn-
chronization is associated with depression and resyn-
chronization is associated with the antidepressant effects
of bright light [44]. There are reasons to suspect that
women with perinatal depression might have circadian
malsychronization. During pregnancy and postpartum,
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light conditions in an effort to get sleep they may not be
getting during the night. These conditions may be even
more exaggerated in perinatal depression, where fatigue
and anhedonia may severely limit daily activities. There
has been limited investigation of the chronobiology of
perinatal depression, though one recent study suggests
that both amplitude and timing of melatonin secretion
may be dysregulated in women with perinatal depression
compared to non-depressed perinatal women [45].
Third, there is emerging evidence that impaired activa-
tion of serotonergically targeted circuits may be involved
in the pathophysiology of PPD [46,47], which could be
corrected with bright light treatment. For example, there
is recent fMRI evidence that activation in these areas is
abnormal in depressed vs. non-depressed mothers when
responding to their newborns’ cries [48,49]. Indeed, pre-
vious studies have implicated alterations in tryptophan
(a serotonin precursor), estrogen, and hypothalamic pi-
tuitary adrenal (HPA) axis activity during the perinatal
period as possible mediators of serotonin dysregulation
[50-53]. Additionally, studies have found that genetic
polymorphisms of the 5-HTT gene are associated with
variations in PPD [54,55], and increased vulnerability to
development of depression in pregnancy and the post-
partum [9]. Conversely, the SSRIs have been prescribed
for perinatal depression [7], and have resulted in
improvements in maternal role functioning in women
with PPD [56,57].
There is some compelling evidence that the anti-
depressant effect of bright light therapy is mediated by
serotonergic mechanisms. Studies have shown that the
antidepressant effects of light therapy are reversed fol-
lowing tryptophan depletion [58]. Because tryptophan is
a precursor to serotonin synthesis, tryptophan depletion
reduces availability of serotonin in the brain, which in
turn has been associated with emergence of depressive
symptoms [59]. Using this established paradigm, recent
work has illustrated that the mood lowering effect of
tryptophan depletion in healthy women is completely
blocked by carrying out the study in bright light (3,000
lux) vs. dim light (10 lux) [60]. Bright light therapy may
provide a means to improve regulation of the serotoner-
gic system in women with perinatal depression, and
bright light therapy poses far less risk to the developing
baby and newborn than current pharmacotherapy.
Fourth, there is evidence that perinatal depression may
be influenced by alterations in estrogen, which could be
corrected with bright light. The close relationship be-
tween estrogen and the serotonin system may provide
some rationale for findings that some women have
increased susceptibility to mood symptoms during periods
of hormonal fluctuation, and that estrogen treatment has
been shown to be effective in mood disorders, includingpostpartum depression [61,62]. It is clear from previous work
that sex hormones such as estrogen and progesterone -
which rise greatly during pregnancy, and then show a
sharp drop immediately after parturition - may play a role
in the etiology of perinatal depression [9].
There is limited evidence that bright light therapy may
be associated with stimulation of luteinizing hormone
(LH), a gonadotropin involved in the production of es-
trogen [63]. The therapeutic benefit of light therapy for
perinatal depression may therefore involve modulation
of estrogen via stimulation of LH.
Fifth, bright light could alleviate co-morbidities of fa-
tigue and sleep disturbance which might be especially
problematic for perinatal depression, when the effects of
sleep loss have consequences for both mother and baby.
There appears to be an association between short sleep
duration and adverse maternal and fetal outcomes
[64-66], and limited evidence also suggests an associa-
tion between sleep problems and maternal depression
[67]. Indeed, fatigue and sleep disturbances are used
diagnostically in the evaluation of perinatal depres-
sion, and are some of the most commonly reported
symptoms in women with PPD [68]. Studies indicate
that women with perinatal depression report substan-
tially poorer sleep than matched healthy antepartum
and postpartum women [69-72]. Evidence indicates
that bright light therapy may decrease daytime fatigue
partly via improvement of sleep [73], and/or improved
daytime alertness [37,38,74,75].
Notwithstanding the prevalence of perinatal depres-
sion and compelling rationales for its treatment with
bright light, we are aware of only five studies of the
effects of bright light therapy on perinatal depres-
sion. Three studies were randomized controlled trials
and two were open trials. These studies will now be
briefly reviewed.
Studies of the efficacy of bright light therapy for
antepartum depression
The general characteristics of studies of bright light
treatment for antepartum depression are summarized in
Table 1. Results from an open trial by Oren and collea-
gues [76] showed a significant decrease (by 49%) from
baseline in Hamilton Depression Rating Scale (HDRS),
Seasonal Affective Disorders Version (SIGH-SAD) after
3 weeks of 10,000 lux bright light therapy. The light was
administered for 60 min/day, beginning within 10 min
of awakening (n= 16). In a subset of participants (n=7)
who continued treatment for 5 weeks, mean scores on the
SIGH-SAD decreased by 59% from baseline. Compliance
was monitored by requiring subjects to call an answering
machine daily to report their light use.
Expanding from this initial work, Epperson and collea-
gues conducted a randomized controlled trial in which
Table 1 Studies of the efficacy of light therapy for perinatal depression
Antepartum depression
Oren et al. [76] Epperson et al. [24] Wirtz-Justice et al. [77]
Subjects (n) 16 10 27
Treatment duration (weeks) 3 5 5
Group randomization No Yes Yes
Time of light sessions Morning: beginning within
10 min of awakening
Morning: beginning within
10 min of awakening
Morning: beginning within
10 min of awakening
Duration of light sessions (min) 60 60 60
Intensity of light treatment (lux) 10,000 7,000 7,000
Blind ratings Yes Yes Yes
Diagnosis of depression SIGH-SAD≥ 20 SIGH-SAD≥ 20 SIGH-SAD≥ 20
Main outcome measure(s) SIGH-SAD SIGH-SAD SIGH-SAD, HDRS
Postpartum depression
Corral et al. 2000 [78] Corral et al. 2007 [79]
Subjects (n) 2 15
Treatment duration (weeks) 4 6
Group randomization No Yes
Time of light sessions Morning: between 7:00 am
and 9:00 am
Morning: between 7:00 am
and 9:00 am
Duration of light sessions (min) 30 60
Intensity of light treatment (lux) 10,000 10,000
Blind ratings No Yes
Diagnosis of depression HDRS =28,29 SIGH-SAD≥ 15
Main outcome measure(s) HDRS SIGH-SAD
HDRS =Hamilton Depression Rating Scale (Hamilton, 1967), SIGH–SAD= Structured Interview Guide for the Hamilton Depression Rating Scale, Seasonal Version
(Williams, 1988).
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either 7,000 lux (active, n=5) or 500 lux (placebo, n=5)
light [24] for 5 weeks. The treatments were administered
for 60 min/day, beginning within 10 min of awakening. To
check compliance, subjects called the research clinic daily
to log in the time of treatment. SIGH-SAD scores were
reduced similarly by bright light (17.3) and the dimmer
light (16.6).
Wirz-Justice and colleagues recently conducted a lar-
ger randomized controlled trial, in which 27 women
with antepartum depression were randomized to 5
weeks of active treatment (7,000 lux bright light, n= 16),
or placebo (70 lux dim red light, n= 11). The treatments
were administered for 60 min/day, beginning within 10
min of awakening [77]. Compliance was monitored with
participant self-reported daily treatment logs. Partici-
pants receiving the bright light treatment showed signifi-
cantly greater improvement in HDRS with Atypical
Depression Supplement (SIGH-ADS) scores than those
in the placebo treatment, and categorical analysis
revealed that the response rate (HDRS ≥ 50% improve-
ment) at week 5 was significantly greater for bright light
(81.3%) than for placebo (45.5%). However, no significant
differences between treatments were found in self-reported ratings of depression which included the
Montgomery-Asberg Depression Rating Scale (MADRS)
and the Beck depression Inventory.
Studies of the efficacy of bright light therapy for
postpartum depression
General characteristics of studies of bright light treat-
ment for postpartum depression are summarized in
Table 1. In an open trial by Corral et al. (2000) (n= 2),
both participants showed substantial clinical improve-
ment (75% reduction in HDRS scores) following 4 weeks
of 10,000 lux bright light treatment administered for 30
min between 7:00 am and 9:00 am [78]. However, a
randomized controlled trial study by Corral et al., (2007)
showed no differences between bright light treatment
(10,000 lux, n=10) and placebo (600 lux dim red light,
n=5), administered for 6 weeks for 30 min/day between
7:00 am and 9:00 am. Both treatments elicited a 49%
reduction in SIGH-SAD scores [79]. Also, similar increases
in SIGH-SAD scores were found following withdrawal of
the treatments.
In this study, participants were asked to verbally re-
port their treatment compliance weekly to the study
physician.
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In summary, antidepressant effects of bright light are
well established, and there are several rationales for
expecting that bright light might also be efficacious for
perinatal depression. In pregnant and/or new mothers,
bright light treatment could potentially offset insufficient
low levels of light exposure; pathological hormonal pro-
files; co-morbidities, including disturbed sleep and fa-
tigue; and serotonergic dysregulation which has been
linked to inadequate maternal behavior.
However, the efficacy of light therapy for perinatal de-
pression has been reported in only five published studies,
which have produced mixed results. These studies have had
numerous limitations. First, only three of the five stu-
dies used a randomized controlled parallel group design.
Second, the sample sizes have been small, perhaps due
partly to difficulties in recruiting participants from this
population. Third, participant adherence in these studies
was only measured via participant self-reports. Adherence
may be particularly problematic for this population, who
have clear logistical obstacles to treatment. Fourth,
studies have not addressed co-morbidities that light
could alleviate, including anxiety [80,81], disturbed
sleep, and fatigue.
Large randomized controlled trials are needed to de-
termine whether bright light therapy elicits significant
improvement in perinatal depression. For many women
suffering from antepartum or postpartum depression,
bright light is likely preferable to other types of treat-
ment, but further research is needed to address ques-
tions about the feasibility of bright light treatment for
these women. Comparative effectiveness trials would also
fill a gap in existing literature, and may provide an import-
ant component of the overall treatment paradigm for
women with perinatal depression. More targeted interven-
tions may be feasible, perhaps with a mixed modalities
treatment approach, for treating women with depression
during pregnancy and/or postpartum. Additionally, fur-
ther research is needed to determine potential mecha-
nisms of the therapeutic effects of bright light therapy for
perinatal depression.
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